Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Perspectives for clinical use of engineered human host defense antimicrobial peptides.

Pachón-Ibáñez ME, Smani Y, Pachón J, Sánchez-Céspedes J.

FEMS Microbiol Rev. 2017 May 1;41(3):323-342. doi: 10.1093/femsre/fux012.

2.

HIV-Enhancing and HIV-Inhibiting Properties of Cationic Peptides and Proteins.

Cole AM, Cole AL.

Viruses. 2017 May 15;9(5). pii: E108. doi: 10.3390/v9050108. Review.

3.

Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates.

Mikulak J, Di Vito C, Zaghi E, Mavilio D.

Front Immunol. 2017 Mar 23;8:314. doi: 10.3389/fimmu.2017.00314. eCollection 2017. Review.

4.

The vaginal microbiota, host defence and reproductive physiology.

Smith SB, Ravel J.

J Physiol. 2017 Jan 15;595(2):451-463. doi: 10.1113/JP271694. Epub 2016 May 5.

PMID:
27373840
5.

The Role of Cationic Polypeptides in Modulating HIV-1 Infection of the Cervicovaginal Mucosa.

Cole AL, Cole AM.

Antibiotics (Basel). 2014 Nov 26;3(4):677-93. doi: 10.3390/antibiotics3040677. Review.

6.

Another functional frame-shift polymorphism of DEFB126 (rs11467497) associated with male infertility.

Duan S, Shi C, Chen G, Zheng JF, Wu B, Diao H, Ji L, Gu Y, Xin A, Wu Y, Zhou W, Miao M, Xu L, Li Z, Yuan Y, Wang P, Shi H.

J Cell Mol Med. 2015 May;19(5):1077-84. doi: 10.1111/jcmm.12502. Epub 2015 Feb 27.

7.

Retrocyclins neutralize bacterial toxins by potentiating their unfolding.

Kudryashova E, Seveau S, Lu W, Kudryashov DS.

Biochem J. 2015 Apr 15;467(2):311-20. doi: 10.1042/BJ20150049.

8.

A hybrid cationic peptide composed of human β-defensin-1 and humanized θ-defensin sequences exhibits salt-resistant antimicrobial activity.

Olli S, Nagaraj R, Motukupally SR.

Antimicrob Agents Chemother. 2015 Jan;59(1):217-25. doi: 10.1128/AAC.03901-14. Epub 2014 Oct 27.

9.

Fusion of protegrin-1 and plectasin to MAP30 shows significant inhibition activity against dengue virus replication.

Rothan HA, Bahrani H, Mohamed Z, Abd Rahman N, Yusof R.

PLoS One. 2014 Apr 10;9(4):e94561. doi: 10.1371/journal.pone.0094561. eCollection 2014.

10.

Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages.

Varchetta S, Lusso P, Hudspeth K, Mikulak J, Mele D, Paolucci S, Cimbro R, Malnati M, Riva A, Maserati R, Mondelli MU, Mavilio D.

Retrovirology. 2013 Dec 13;10:154. doi: 10.1186/1742-4690-10-154.

11.

Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Mulder KC, Lima LA, Miranda VJ, Dias SC, Franco OL.

Front Microbiol. 2013 Oct 31;4:321. doi: 10.3389/fmicb.2013.00321. eCollection 2013. Review.

12.
13.

Cationic host defence peptides: potential as antiviral therapeutics.

Gwyer Findlay E, Currie SM, Davidson DJ.

BioDrugs. 2013 Oct;27(5):479-93. doi: 10.1007/s40259-013-0039-0. Review.

14.

The cyclic cystine ladder in θ-defensins is important for structure and stability, but not antibacterial activity.

Conibear AC, Rosengren KJ, Daly NL, Henriques ST, Craik DJ.

J Biol Chem. 2013 Apr 12;288(15):10830-40. doi: 10.1074/jbc.M113.451047. Epub 2013 Feb 21.

15.

HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected].

Eissmann K, Mueller S, Sticht H, Jung S, Zou P, Jiang S, Gross A, Eichler J, Fleckenstein B, Reil H.

PLoS One. 2013;8(1):e54452. doi: 10.1371/journal.pone.0054452. Epub 2013 Jan 22. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/b46459e1-73ff-4b75-8f24-264cbcf4a5a9.

16.

Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1.

Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA, Yusof R.

BMC Infect Dis. 2012 Nov 21;12:314. doi: 10.1186/1471-2334-12-314.

17.

The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa.

Eade CR, Cole AL, Diaz C, Rohan LC, Parniak MA, Marx P, Tarwater PM, Gupta P, Cole AM.

Am J Reprod Immunol. 2013 Feb;69(2):150-8. doi: 10.1111/aji.12036. Epub 2012 Nov 20.

18.

Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1.

Gupta P, Lackman-Smith C, Snyder B, Ratner D, Rohan LC, Patton D, Ramratnam B, Cole AM.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):391-6. doi: 10.1089/AID.2012.0135. Epub 2012 Oct 10.

19.

θ-Defensins: cyclic peptides with endless potential.

Lehrer RI, Cole AM, Selsted ME.

J Biol Chem. 2012 Aug 3;287(32):27014-9. doi: 10.1074/jbc.R112.346098. Epub 2012 Jun 14.

20.

Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Gupta P, Ratner D, Ding M, Patterson B, Rohan LC, Reinhart TA, Ayyavoo V, Huang X, Patton DL, Ramratnam B, Cole AM.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):455-61.

Supplemental Content

Support Center